[A18-57] Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 13.02.2019
Commission awarded on 19.09.2018 by the Federal Joint Committee (G-BA).
Adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy
Added benefit not proven for the 2 subindications (no liver cirrhosis or stage Child-Pugh A, Child-Pugh B)
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-02.After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-19||Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-15||Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57||Commission completed|
|G15-06||Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|A16-63||Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-122||Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|